Atossa Therapeutics, Inc.ATOSNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
-2.40%
↓ 107% below average
Average (39q)
35.61%
Historical baseline
Range
High:490.15%
Low:-103.53%
CAGR
-9.2%
Structural decline
| Period | Value |
|---|---|
| Q3 2025 | -2.40% |
| Q2 2025 | 32.36% |
| Q1 2025 | 22.16% |
| Q4 2024 | -0.26% |
| Q3 2024 | -3.97% |
| Q2 2024 | -5.20% |
| Q1 2024 | -33.71% |
| Q4 2023 | 26.57% |
| Q3 2023 | 20.57% |
| Q2 2023 | 5.62% |
| Q1 2023 | -16.93% |
| Q4 2022 | -18.16% |
| Q3 2022 | 50.31% |
| Q2 2022 | 129.02% |
| Q1 2022 | -20.14% |
| Q4 2021 | -21.23% |
| Q3 2021 | -39.02% |
| Q2 2021 | 162.99% |
| Q1 2021 | -36.96% |
| Q4 2020 | 42.07% |
| Q3 2020 | 0.35% |
| Q2 2020 | 76.14% |
| Q1 2020 | -4.86% |
| Q4 2019 | -41.42% |
| Q3 2019 | -35.52% |
| Q2 2019 | 79.98% |
| Q1 2019 | 70.85% |
| Q4 2018 | -40.26% |
| Q3 2018 | -3.13% |
| Q2 2018 | 211.64% |
| Q1 2018 | 116.80% |
| Q4 2017 | -70.74% |
| Q3 2017 | -9.91% |
| Q2 2017 | 51.40% |
| Q1 2017 | 48.53% |
| Q4 2016 | 331.13% |
| Q3 2016 | -49.70% |
| Q2 2016 | 12.68% |
| Q1 2016 | 490.15% |
| Q4 2015 | -103.53% |